search
Back to results

Thyroid Hormones in ADPKD (REORIENTED)

Primary Purpose

Autosomal Dominant Polycystic Kidney

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Blood sampling
Sponsored by
Mario Negri Institute for Pharmacological Research
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Autosomal Dominant Polycystic Kidney

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male and female ≥18 years old; Diagnosis of ADPKD based on renal ultrasonography or genetic test; Written informed consent Exclusion Criteria: Diagnosis of Hashimoto's disease, hyperthyroidism or pituitary disease or any other condition undergoing levothyroxine replacement Patient with hypothyroidism treated with drug therapy Active treatment with Tolvaptan and/or Octreotide-LAR; Regular treatment with amiodarone, lithium, interferon or immunosuppressive drugs including steroids; Active malignancy or acute or chronic inflammatory disease, HIV; Dialysis or kidney transplantation; Diabetes mellitus; Hypocaloric diet or current dietary approaches to obtain weight loss. Legal incapacity or any evidence that the patient will not be able to understand the study aims and procedures.

Sites / Locations

  • Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"Recruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ADPKD patients

Arm Description

The study will include 90 patients with diagnosis of ADPKD based on renal ultrasonography findings or genetic test. Specifically, five groups of patients will be identified according to KDIGO classification: 18 subjects with normal or high renal function: eGFR ≥90 ml/min/1.73m2 - CKD G1 stage 18 subjects with mildly decreased renal function: eGFR 89-60 ml/min/1.73m2 - CKD G2 stage 18 subjects with mildly to moderately decreased renal function: eGFR 59 to 45 ml/min/1.73m2 - CKD G3a stage 18 subjects with moderately to severely decreased renal function: eGFR 44 to 30 ml/min/1.73m2 - CKD G3b stage 18 subjects with severely decreased renal function: eGFR 29 to 15 ml/min/1.73m2 - CKD G4 stage.

Outcomes

Primary Outcome Measures

Serum levels of total and free triiodothyronine (T3).
Serum levels of total and free L-thyroxine (T4).
Serum levels of total and free thyroid stimulating hormone (TSH).
Serum levels of total and free reverse T3 (rT3).

Secondary Outcome Measures

Full Information

First Posted
December 5, 2022
Last Updated
February 2, 2023
Sponsor
Mario Negri Institute for Pharmacological Research
search

1. Study Identification

Unique Protocol Identification Number
NCT05646420
Brief Title
Thyroid Hormones in ADPKD
Acronym
REORIENTED
Official Title
Deciphering the Role of Thyroid Hormones in Autosomal Dominant Polycystic Kidney Disease
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2023 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mario Negri Institute for Pharmacological Research

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic, rare and life-threatening disease, characterized by the pathological formation of multiple fluid-filled cysts that arise from renal tubules and alter kidney architecture and function. In most patients, the progressive deterioration of renal function ultimately leads to end-stage kidney disease (ESKD) and the need for dialysis or kidney transplantation. Save the conventional anti-hypertensive strategies, there are currently two disease-specific treatments for ADPKD (Tolvaptan and Octreotide-LAR). However, these drugs are only available to patients at high risk of progression to ESKD, while a remarkable number of ADPKD patients progress to ESKD despite the treatments. Cyst formation in ADPKD is determined by mutations in two genes encoding two transmembrane proteins: polycystin1 and polycystin2. The pathogenesis of the disease involves a series of phenotypic alterations, including the de-differentiation of epithelial cells, uncontrolled proliferation and abnormal secretion of fluids in the cysts, metabolic remodeling, all phenomena that lead to the progressive loss of renal structure and function . Therefore, to try to investigate the mechanisms of the disease, the investigators should go in search of pleiotropic molecules capable of simultaneously modulating structure, function and metabolism. Research done so far suggests that thyroid hormones (TH) may also act as pleiotropic modulators in the patho-biology of ADPKD. TH signals play a crucial role in the regulation of cell de-differentiation and cell cycle reactivation, as well as in the metabolism and evolution of cardiac and renal diseases. Interestingly, changes in TH levels have been detected in approximately 80% of patients with chronic renal failure (CKD), whereas patients with ADPKD show a higher incidence of clinical and subclinical hypothyroidism. Despite these evidences, the ability of TH to modulate anti-cystogenic and renoprotective processes in ADPKD has not yet been studied. The objective of this study is to determine the levels of THs in the serum of ADPKD patients with normal renal function and mild, moderate or severe renal dysfunction, and to correlate them with renal functional parameters.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autosomal Dominant Polycystic Kidney

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ADPKD patients
Arm Type
Experimental
Arm Description
The study will include 90 patients with diagnosis of ADPKD based on renal ultrasonography findings or genetic test. Specifically, five groups of patients will be identified according to KDIGO classification: 18 subjects with normal or high renal function: eGFR ≥90 ml/min/1.73m2 - CKD G1 stage 18 subjects with mildly decreased renal function: eGFR 89-60 ml/min/1.73m2 - CKD G2 stage 18 subjects with mildly to moderately decreased renal function: eGFR 59 to 45 ml/min/1.73m2 - CKD G3a stage 18 subjects with moderately to severely decreased renal function: eGFR 44 to 30 ml/min/1.73m2 - CKD G3b stage 18 subjects with severely decreased renal function: eGFR 29 to 15 ml/min/1.73m2 - CKD G4 stage.
Intervention Type
Other
Intervention Name(s)
Blood sampling
Intervention Description
A blood sample of 15 ml will be collected for each patient.
Primary Outcome Measure Information:
Title
Serum levels of total and free triiodothyronine (T3).
Time Frame
Once during the study.
Title
Serum levels of total and free L-thyroxine (T4).
Time Frame
Once during the study.
Title
Serum levels of total and free thyroid stimulating hormone (TSH).
Time Frame
Once during the study.
Title
Serum levels of total and free reverse T3 (rT3).
Time Frame
Once during the study.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female ≥18 years old; Diagnosis of ADPKD based on renal ultrasonography or genetic test; Written informed consent Exclusion Criteria: Diagnosis of Hashimoto's disease, hyperthyroidism or pituitary disease or any other condition undergoing levothyroxine replacement Patient with hypothyroidism treated with drug therapy Active treatment with Tolvaptan and/or Octreotide-LAR; Regular treatment with amiodarone, lithium, interferon or immunosuppressive drugs including steroids; Active malignancy or acute or chronic inflammatory disease, HIV; Dialysis or kidney transplantation; Diabetes mellitus; Hypocaloric diet or current dietary approaches to obtain weight loss. Legal incapacity or any evidence that the patient will not be able to understand the study aims and procedures.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christodoulos Xinaris
Phone
+3903542131
Email
christodoulos.xinaris@marionegri.it
Facility Information:
Facility Name
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"
City
Ranica
State/Province
BG
ZIP/Postal Code
24020
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matias Trillini, MD
Phone
0039 035 45351
Email
matias.trillini@marionegri.it

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Thyroid Hormones in ADPKD

We'll reach out to this number within 24 hrs